GentiBio has raised $157 million in a series A funding round to advance its type I diabetes therapy.
GentiBio is focused on developing engineered regulatory T cell (Treg) therapies for immunological applications, with a lead program aimed at creating a functional cure for Type I diabetes. Other pipeline programs target autoimmunity and autoinflammation, including work in autoimmune liver disease and acute respiratory distress syndrome (ARDS).
“Tregs play a vital role in controlling immune responses but are a rare and heterogenous population that is challenging to isolate and purify at scale,” said Adel Nada, President and Chief Executive Officer of GentiBio, in a statement. “GentiBio engineered Tregs created from abundant autologous and allogeneic T cell sources have the potential to overcome scalability and phenotypic inconsistency issues that are intrinsic to Tregs sorted from peripheral blood. With the Series A financing, we are focused on advancing our programs with a uniquely scalable manufacturing process that produces stable and disease specific engineered Tregs that are also tunable once infused in patients.”
The company plans to begin IND-enabling studies for its diabetes candidate before the end of the year.